Core Viewpoint - The Schall Law Firm is investigating claims against Insulet Corporation for potential violations of securities laws following a manufacturing issue with its Omnipod® 5 Pods, which led to a significant drop in share price [1][2]. Group 1: Investigation Details - The investigation focuses on whether Insulet made false or misleading statements or failed to disclose important information to investors [2]. - On March 12, 2026, Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods due to a manufacturing issue identified through ongoing product monitoring [2]. - Following this announcement, Insulet's shares fell by nearly 6.9% the next day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [3].

Core Viewpoint - A securities fraud class action lawsuit has been filed against NuScale Power Corporation, alleging that the company made false statements regarding its commercialization strategy and the experience of its partner, ENTRA1 Energy LLC, during the class period from May 13, 2025, to November 6, 2025 [1][2][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Oregon under the case caption Truedson v. NuScale Power Corporation, et al, Case No. 3:26-cv-00328 (D. Or.) [1]. - Investors have until April 20, 2026, to file for lead plaintiff status [1][3]. Allegations - The complaint alleges that: 1. ENTRA1 Energy LLC had no significant experience in building, financing, or operating nuclear power projects [2]. 2. NuScale entrusted its commercialization and deployment of its Power Module to ENTRA1, which lacked relevant experience [2]. 3. Misleading statements were made regarding the qualifications of ENTRA1, which were actually related to another entity, the Habboush Group, without significant nuclear experience [2]. 4. NuScale's commercialization strategy faced undisclosed risks of failure and regulatory challenges [2]. Financial Impact - On November 6, 2025, NuScale reported a significant increase in general and administrative expenses, which rose over 3,000% to $519 million, primarily due to a $495 million payment to ENTRA1 [5]. - This led to a quarterly net loss of $532 million, up from $46 million in the prior year period, causing the stock price to drop by $5.45 per share, or approximately 14.4%, from $37.91 to $32.46 [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Trip.com Group Limited (NASDAQ: TCOM) for allegedly making materially false and misleading statements regarding its business operations and regulatory risks [1][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Trip.com securities between April 30, 2024, and January 13, 2026, with a deadline of May 11, 2026, to seek lead plaintiff status [1][4]. - The case is titled De Wilde v. Trip.com Group Limited, et al, and is being heard in the United States District Court for the Eastern District of New York [1]. Allegations - The complaint alleges that Trip.com failed to disclose significant regulatory risks associated with its monopolistic business practices, leading to misleading positive statements about the company's prospects [2][4]. - Specific allegations include the company's understatement of regulatory risks and the misleading nature of its optimistic statements regarding business operations [2]. Stock Performance - Following a January 14, 2026, article by Bloomberg revealing an investigation into Trip.com for alleged antitrust conduct, the company's stock price dropped by $12.90, or approximately 17.05%, closing at $62.78 per share [3]. Investor Actions - Investors who have lost money on their Trip.com investments are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential recovery options at no cost [2][4]. - Investors may choose to seek lead plaintiff status or remain as absent class members, with the lead plaintiff representing the interests of the class in the litigation [7].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Gemini Space Station, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the period from September 12, 2025, to February 17, 2026 [3][4]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case name Methvin v. Gemini Space Station, Inc., with a deadline for investors to file for lead plaintiff status set for May 18, 2026 [1][4]. - The allegations include that Gemini overstated the viability of its core business as a crypto platform and its commitment to expanding international operations, leading to an inflated perception of its post-IPO financial prospects [3][4]. Group 2: Stock Performance - Following the announcement of a corporate pivot to "Gemini 2.0" on February 5, 2026, which included a 25% workforce reduction, Gemini's Class A common stock fell by $0.64, or 8.72%, closing at $6.70 per share [4][6]. - On February 17, 2026, after announcing the departure of key executives and revealing a 40% increase in operating expenses, the stock price dropped by $0.97, or 12.9%, closing at $6.585 per share [7][4]. - At the time of the complaint filing, Gemini's Class A common stock was trading at $5.96 per share, representing a 78.7% decline from its IPO price of $28.00 per share [8].

Core Viewpoint - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ImmunityBio, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding its lead product, Anktiva [1][4]. Company Overview - ImmunityBio, Inc. is a biotechnology company that specializes in developing and commercializing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations - The class action lawsuit claims that ImmunityBio made false and misleading statements about Anktiva, including unsubstantiated claims that it would allow all NMIBC patients to be cancer-free long-term and that it functions as a cancer vaccine [4]. - The lawsuit also alleges that Dr. Patrick Soon-Shiong, ImmunityBio's Executive Chairman, materially overstated Anktiva's capabilities [4]. Regulatory Issues - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional materials for Anktiva misbranded the drug and violated the Federal Food, Drug, and Cosmetic Act. This letter raised public health concerns and led to a 21% drop in ImmunityBio's stock price [5]. Class Action Process - Investors who purchased ImmunityBio securities during the specified class period (January 19, 2026, to March 24, 2026) have until May 26, 2026, to apply to be lead plaintiffs in the class action lawsuit [1][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Vital Farms, Inc. (NASDAQ: VITL) during the specified Class Period, alleging securities fraud due to misleading statements and failure to disclose risks associated with the rollout of a new enterprise resource planning (ERP) system [1][5]. Group 1: Lawsuit Details - The class action lawsuit covers purchasers of Vital Farms securities from May 8, 2025, to February 26, 2026, inclusive [1]. - The lawsuit claims that Vital Farms downplayed the risks and impacts of delays related to its ERP system rollout, which ultimately led to the company missing its full year 2025 earnings guidance and earnings per share consensus [5]. - The misleading statements made by the defendants are alleged to have materially affected investors, resulting in damages when the true details became public [5]. Group 2: Participation Information - Investors who purchased Vital Farms securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by May 26, 2026, to represent the class in the lawsuit [3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements including over $438 million secured in 2019 alone [4].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses following its IPO on October 31, 2025, leading to significant stock price declines [1][3][4]. Group 1: IPO Details - Navan conducted its IPO on October 31, 2025, issuing nearly 37 million shares at an offering price of $25.00 per share [2]. - The lawsuit claims that the offering documents were materially false and/or misleading, particularly regarding future sales and marketing expenses [3]. Group 2: Financial Performance and Stock Impact - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses, rising to nearly $95 million from $68.5 million in the previous quarter [4]. - Following the earnings report, Navan's stock price fell nearly 12%, and by the time of the lawsuit, the stock had traded as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [4][5]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan common stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - The article discusses a class action lawsuit against NuScale Power Corporation, alleging that the company and its executives made misleading statements regarding their commercialization partnership with ENTRA1 Energy LLC, which has resulted in significant financial losses for investors [1][3]. Group 1: Class Action Lawsuit Details - Investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025, can seek appointment as lead plaintiff in the class action lawsuit [1]. - The lawsuit, titled Truedson v. NuScale Power Corporation, accuses NuScale and certain executives of violating the Securities Exchange Act of 1934 [1]. - The lawsuit claims that NuScale's reliance on ENTRA1, which lacked experience in nuclear power projects, exposed the company to undisclosed risks [3]. Group 2: Financial Impact - On November 6, 2025, NuScale reported a more than 3,000% increase in general and administrative expenses, rising to $519 million from $17 million in the previous year, primarily due to a $495 million payment to ENTRA1 [4]. - The company's quarterly net loss surged to $532 million, compared to $46 million in the prior year [4]. - Following the financial disclosures, NuScale's Class A share price dropped over 12% within two days [4]. Group 3: Company Background and Legal Representation - NuScale's core technology, the NuScale Power Module, is designed for energy generation within a broader power plant context [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, has a strong track record in prosecuting investor class actions and has recovered significant amounts for investors in the past [5][7].

Core Viewpoint - Oracle Corporation is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding its financial health and AI-related infrastructure costs [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Jackson County Employees' Retirement System v. Oracle Corporation and covers purchasers of Oracle securities from June 12, 2025, to December 16, 2025 [1]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit also references a previously filed case, Barrows v. Oracle Corporation, which is still pending [1]. Group 2: Allegations Against Oracle - The lawsuit alleges that Oracle's revenue and remaining performance obligations (RPO) growth related to AI infrastructure would cost tens of billions more than disclosed, requiring Oracle to take on hundreds of billions in additional long-term lease commitments [3]. - It is claimed that Oracle would need to raise tens of billions in additional capital, leading to dilution for investors and increased borrowing costs [3]. - The lawsuit asserts that Oracle's AI-related infrastructure business has materially lower profit margins and is riskier than previously portrayed [3]. Group 3: Financial Disclosures and Impact - On December 10, 2025, Oracle disclosed that its capital expenditures had surged to $35.5 billion over the trailing four quarters, significantly higher than the $10.7 billion in the prior year [4]. - Oracle's negative free cash flow more than doubled sequentially to negative $13.2 billion [4]. - During an earnings call, Oracle's executive revealed expectations of capital expenditures reaching $50 billion in fiscal 2026, double the previously communicated benchmark of $25 billion [4]. - On December 11, 2025, Oracle reported an increase in additional lease obligations to $248 billion, primarily related to data centers and cloud capacity, which were not reflected in prior balance sheets [5]. - Following these disclosures, Oracle's stock price fell by 15% over two trading days, with continued declines as further negative news emerged [5].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against ADMA Biologics, Inc., focusing on possible violations of federal securities laws and unlawful business practices by the company and its senior management [1][2]. Group 1: Investigation Details - The investigation was prompted by a report from Culper Research on March 24, 2026, alleging that ADMA engaged in "Channel Stuffing" and had undisclosed related party distributors, with a reported growth of +20% in 2025 being misleading as the actual growth was only -3% [2]. - The report indicated that two high-level employees from one of ADMA's largest distributors confirmed that ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms, allowing the company to book revenues that did not reflect actual sales [2]. Group 2: Market Reaction - Following the publication of the report, ADMA's share price fell by $2.26, or approximately 17%, dropping from $13.59 on March 23, 2026, to close at $11.33 on March 24, 2026 [2].